|
2-3 toe syndactyly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
4-5 toe syndactyly
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abdominal Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Four transgenic fish developed abdominal tumors between 4 and 6 months of age, and histologic analysis revealed lobulated arrangements of neoplastic cells with expression of the MYCN transgene.
|
15492244 |
2004 |
|
Abdominal Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Multiparametric MR imaging was performed of abdominal tumors found in the TH-MYCN model.
|
23169794 |
2013 |
|
Accessory spleen
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acute Megakaryocytic Leukemias
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In contrast, MYCN (neuroblastoma-derived oncogene) was expressed in TMD at a significantly greater level than in AMKL.
|
15180862 |
2004 |
|
Adenocarcinoma
|
0.030 |
GeneticVariation
|
group |
BEFREE |
A 30-fold amplification of the N-myc gene was found in a tumor histopathologically and histochemically verified as a typical adenocarcinoma.
|
3020069 |
1986 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
N-myc gene amplification was found in an adenocarcinoma cell line, VMRC-LCD.
|
1622116 |
1992 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> We investigated MYCN-regulated molecular pathways in castration-resistant prostate cancer (CRPC) classified by morphologic criteria as adenocarcinoma or neuroendocrine to extend the molecular phenotype, establish driver pathways, and identify novel approaches to combination therapy for neuroendocrine prostate cancer (NEPC).<b>Experimental Design and Results:</b> Using comparative bioinformatics analyses of CRPC-Adeno and CRPC-Neuro RNA sequence data from public data sets and a panel of 28 PDX models, we identified a MYCN-PARP-DNA damage response (DDR) pathway that is enriched in CRPC with neuroendocrine differentiation (NED) and CRPC-Neuro.
|
29138344 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
N-myc gene amplification in adenocarcinoma of the lung is extremely rare, therefore we report herein on this case.
|
1622116 |
1992 |
|
Adenocarcinoma of pancreas
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Adenocarcinoma of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We define N-Myc and activated AKT1 as oncogenic components sufficient to transform human prostate epithelial cells to prostate adenocarcinoma and NEPC with phenotypic and molecular features of aggressive, late-stage human disease.
|
27050099 |
2016 |
|
Adenoid Cystic Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
The mutational landscape of adenoid cystic carcinoma.
|
23685749 |
2013 |
|
Adrenal Gland Pheochromocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The involvement of the MYC-MAX-MXD1 network in the development and progression of neural crest cell tumors is further supported by the lack of functional MAX in rat PCC (PC12) cells and by the amplification of MYCN in neuroblastoma and suggests that loss of MAX function is correlated with metastatic potential.
|
21685915 |
2011 |
|
Adult Acute Myeloblastic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of both UROD and MYCN predicts poor overall survival and unfavorable outcomes in adult AML.
|
28768907 |
2017 |
|
Adult Burkitt Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Nevertheless, due to the overlapping clinic, morphology and immunohistochemistry (apart for MYC versus MYCN protein expression) of both sub-groups, the described cases represent bona fide BL according to the current criteria of the World Health Organization.
|
31748534 |
2019 |
|
Adult Ependymoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Taking these findings into account, we suggest to designate this molecular subgroup spinal ependymoma with MYCN amplification, SP-EPN-MYCN.
|
31414211 |
2019 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
NAMPT inhibitors were potently cytotoxic, inducing apoptosis and significantly extended the survival of mice bearing MYCN-amplified patient-derived glioblastoma orthotopic xenografts.
|
27076630 |
2016 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation.
|
12845671 |
2003 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
NDRG2, a member of the N-Myc downstream-regulated gene family, was shown to be a putative tumor suppressor gene in glioblastoma and other cancers.
|
21912936 |
2012 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Gene amplification and rearrangements are discussed through review of recent work on the N-myc gene in neuroblastoma and the epidermal growth factor receptor (EGFR) gene in glioblastoma.
|
3059215 |
1988 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We show that MYC or MYCN amplification in patient-derived glioblastoma stem-like cells (GSCs) generates sensitivity to PARPi via Myc-mediated transcriptional repression of CDK18, while most tumors without amplification are not sensitive.
|
31266951 |
2019 |
|
Adult Glioblastoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.
|
23539269 |
2013 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
|
31754113 |
2019 |
|
Adult Glioblastoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
This finding also confirms the importance of impairment of the MYC/MAX/MXD1 axis in the development of aggressive neural tumors, because MYCN overexpression is an established genetic hallmark of malign neuroblastoma, and it is likely that MXI1 plays a relevant role in the development of medulloblastoma and glioblastoma.
|
22706201 |
2012 |